Factors Predictive of Survival after First Relapse or Progression in Advanced Epithelial Ovarian Carcinoma: A Prediction Tree Analysis-Derived Model with Test and Validation Groups

This publication has 17 references indexed in Scilit:

• Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study
  International Journal of Gynecologic Cancer, 1997
• Chemotherapy for gynecologic malignancies
  Current Opinion in Oncology, 1995
• Tree-structured prediction for censored survival data and the cox model
  Journal of Clinical Epidemiology, 1995
• The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer
  Cancer, 1993
• Is Serum CA 125 at the Time of Relapse a Prognostic Indicator for Further Survival Prognosis in Patients with Ovarian Cancer?
  Gynecologic Oncology, 1993
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
  Journal of Clinical Oncology, 1992
• Long-term survival in ovarian cancer
  European Journal of Cancer and Clinical Oncology, 1991
• The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing
  International Journal of Gynecologic Cancer, 1991
• Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
  Journal of Clinical Oncology, 1991
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
  Journal of Clinical Oncology, 1991